2023 Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19 Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
2022 Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV) Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19 Enanta Pharmaceuticals Initiates RSVHR, a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
2021 Enanta Pharmaceuticals Announces Positive Data from Phase 1 Study of EDP-514 in Nucleos(t)ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection Enanta Pharmaceuticals Announces Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic Chronic HBV Patients Enanta Pharmaceuticals Adds COVID-19 to its Pipeline with the Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 Enanta Pharmaceuticals Initiates RSVPEDs, a Phase 2 Clinical Study of EDP-938 in Pediatric Patients with Respiratory Syncytial Virus
2020 Enanta Pharmaceuticals’ HCV Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19
2019 Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in a Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus Enanta Adds Hepatitis B Virus to its Pipeline with the Initiation of Phase 1 Clinical Study of Core Inhibitor EDP-514
2018 Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus
2017 Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) Enanta Announces That AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available in Japan for the Treatment of Chronic Hepatitis C Across All Major Genotypes (GT1-6)
2016 Enanta Pharmaceuticals Announces Positive Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
2015 Enanta Pharmaceuticals and AbbVie Announce European Commission Grants Marketing Authorization for AbbVie’s VIEKIRAX™
2014 Enanta Pharmaceuticals and AbbVie Announce FDA Approves VIEKIRA PAK®, AbbVie’s Combination Drug for the Treatment of Chronic Genotype 1 Hepatitis C Virus